Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.

This randomized study did not show significant difference between perioperative blood loss or blood transfusion requirement by prophylactic
use of rFVIIa in patients with normal hemostasis undergoing pelvic surgery. No adverse events were reported in either group.

– Maadh Aldouri